Home

BIOGEN INC.

CIK 875045 · last filed 2023-09-28

BIOGEN INC. is a corporate insider who has filed 5 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing shows the insider sold $6.0M of SGMO on Sep 28, 2023. Across all open-market trades the lifetime net is −$12.2M, making them a net seller over the disclosed history. The firm reports its address in Cambridge, MA. 84 SEC filings were submitted jointly with SUSAN H ALEXANDER.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

5

Lifetime Open-Market Net

-$12.22M

Filer Profile

Reported Address
225 BINNEY STREET
CAMBRIDGE, MA 02142
Phone
(617) 679-2000
State of Incorporation
DE
Formerly Known As
BIOGEN IDEC INC. (2007–2015)
BIOGEN IDEC INC (2003–2007)
IDEC PHARMACEUTICALS CORP / DE (1997–2003)
IDEC PHARMACEUTICALS CORP / CA (1996–1997)
Related Filers
SUSAN H ALEXANDER — 84 joint filings, latest 2026-02-17
JAMES C MULLEN — 77 joint filings, latest 2010-06-10
GEORGE A SCANGOS — 68 joint filings, latest 2016-07-22
Paul J Clancy — 56 joint filings, latest 2017-04-27
Alfred Sandrock — 48 joint filings, latest 2021-06-09
Priya Singhal — 44 joint filings, latest 2026-02-17
JOHN MICHAEL DUNN — 38 joint filings, latest 2009-02-26
John Cox — 37 joint filings, latest 2016-04-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SANGAMO THERAPEUTICS, INC (SGMO) Delisted 10%+ Owner 17,652,466 $0.18 $3.14M -$12.22M 4 2023-09-28
Bioverativ Inc. (BIVVV) Delisted 10%+ Owner 0 — — $0 1 2017-02-01

Recent Filings

5 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2023-09-28 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Sell (S) −12,000,000 -$6.00M EDGAR
2022-08-31 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Sell (S) −1,000,000 -$5.31M EDGAR
2021-12-10 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Sell (S) −47,320 -$405.1K EDGAR
2021-11-30 SANGAMO THERAPEUTICS, INC (SGMO) Delisted Sell (S) −57,768 -$496.9K EDGAR
2017-02-01 Bioverativ Inc. (BIVVV) Delisted Other (J) −107,975,968 $0 EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.